Pay in 4 interest-free payments of $6.83 Learn more
Ships within 48 hours · Estimated delivery Aug 22 - Aug 27
In the SURMOUNT-1 trial, participants lost between 16% and 22.5% of their body weight depending on dose, results that raised the bar for what many believed was possible with medication-assisted weight loss
Increased Risk of Contamination Injectable medications, once punctured, are more vulnerable to bacterial or fungal contamination
SN, QR, LY, and XinC provided materials and samples
)
TRIUMPH-3 also tracked cardiovascular events, but the results (hazard ratios of 1.12 and 0.82 for two different event composites) were not statistically significant meaning this trial cannot confirm cardiovascular benefit
As a non-peptide compound that is chemically stable in acidic conditions and resistant to enzymatic degradation, orforglipron does not depend on the gastric environment or specific absorption-enhancing conditions for its oral uptake
